# CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

> **NCT04758767** · PHASE1 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CID-103

## Key facts

- **NCT ID:** NCT04758767
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-22
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04758767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04758767, "CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04758767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*